Liang Ye

机构：Nanjing Medical University · ORCID：0000-0002-3035-6265

发表论文 15 篇 · 总被引 343 次 · h-index 7

代表论文

• Metallothionein 1: A New Spotlight on Inflammatory Diseases (2021 · Frontiers in Immunology · 被引 149)
• PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo (2019 · Acta Pharmaceutica Sinica B · 被引 64)
• PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice (2020 · PLoS ONE · 被引 36)
• Immunosuppression Induced by Glutamine Deprivation Occurs via Activating PD-L1 Transcription in Bladder Cancer (2021 · Frontiers in Molecular Biosciences · 被引 28)
• PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations (2019 · Scientific Reports · 被引 20)
• PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer (2020 · Toxicology and Applied Pharmacology · 被引 19)